Taipei will begin implementing designated smoking zones and outdoor negative-pressure smoking rooms in the Ximen and Zhongshan districts this month, marking the first phase of a broader plan to establish 19 such areas citywide. From June 1, Ximen will become the first neighborhood where smoking is banned in public except within these designated rooms, with three facilities already prepared for operation. City officials said additional areas will follow as part of efforts to expand smoke-free spaces.
The announcement drew backlash from smokers, with critics citing limited locations, restricted hours, and capacity concerns, as the rooms operate from 8 a.m. to midnight and accommodate about 10 people, though authorities said they are within a five-minute walk of key locations and align with practices seen in other cities.
Vietnam’s planned introduction of a mixed tobacco excise tax from 2027 is expected to combine a 75% ad valorem rate with a gradually increasing specific tax, adding 2,000 VND ($0.08) per pack annually and reaching 10,000 VND ($0.38) by 2031. The policy aims to reduce smoking rates, increase the tax share of retail prices to nearly 60%, and boost excise revenue, which is projected to more than double to 39.1 trillion VND ($1.5 billion) by 2030. However, officials and experts warn that higher taxes could widen price gaps and push some consumers toward illicit tobacco, which already accounts for an estimated 20–22% of the market and causes annual tax losses of up to 6 trillion VND ($228 million).
Authorities say stronger enforcement will be critical to support the policy, including higher penalties for smuggling and retail violations, expanded oversight of e-commerce sales, and coordinated action among customs, police, and border forces. Recent enforcement efforts have resulted in over 23 million packs of illicit cigarettes seized and more than 1,600 violations recorded, though officials note that trafficking remains widespread and increasingly sophisticated across multiple regions.
Greece launched a digital registry system to monitor the sale of alcohol, tobacco, and vaping products in real time, introducing mandatory registration and compliance tracking for retailers. The platforms alto.gov.gr and events.gov.gr underpin the system, which has already registered more than 88,600 points of sale and over 79,000 businesses, the government said. Under the framework, retailers must submit operational details and receive QR-coded certification, enabling authorities to verify compliance instantly during inspections, with non-registered businesses barred from selling regulated products.
The initiative is aimed at strengthening enforcement and limiting underage access, while bringing tobacco, alcohol, and vaping products under a unified regulatory structure. Officials said the system improves market visibility and enables more targeted inspections, replacing fragmented oversight with continuous digital monitoring and stricter control of retail activity.
Revenue officers in Ireland seized about 11.4 million illicit cigarettes at Dublin Port following a targeted inspection on April 30. The shipment, which arrived from Rotterdam and was declared as cardboard packaging, was flagged through routine risk profiling and uncovered with the assistance of a detector dog and mobile X-ray scanner. The cigarettes, including brands such as Lambert & Butler Silver, Superkings Blue, and Richmond, are estimated to be worth more than €10.8 million, with a potential tax loss to the state of over €8.4 million.
Authorities said investigations are ongoing and noted the seizure forms part of broader efforts to combat illegal tobacco trade and the shadow economy.
Belgium announced it will ban flavored e-cigarettes starting September 1, 2028, allowing only tobacco and neutral flavors under a measure approved by the federal government on April 30. The policy, proposed by Health Minister Frank Vandenbroucke, is aimed at reducing youth vaping by removing flavors, which officials say increase product appeal among teenagers. Government data cited in the decision shows more than one in three individuals aged 15 to 20 have tried e-cigarettes.
The measure follows recommendations from the Superior Health Council and aligns with similar restrictions implemented in the Netherlands. Authorities said the delayed implementation allows time for EU procedures and for retailers to clear existing inventory. Retail groups, including Perstablo, have opposed the move, warning it could expand the illicit market and negatively impact businesses.
Altria Group, Inc. will host its 2026 Annual Meeting of Shareholders via live audio webcast on May 14 at 9 a.m. ET. Shareholders of record as of March 25 will be able to vote electronically and submit questions during the virtual meeting, while non-shareholders may attend as guests without participation rights. The company encourages shareholders to vote in advance using methods outlined in its proxy materials, and said an archived webcast will be available after the event, along with supporting business and financial resources on its investor website.
A coalition of Indonesian civil society groups rejected a government proposal to expand the country’s tobacco excise system by adding a new tariff tier, arguing it could undermine public health objectives and increase corruption risks. The Coalition Save Our Surroundings (SOS), which includes CISDI, Seknas FITRA, and Indonesia Corruption Watch, said the plan contradicts the primary purpose of excise policy of controlling consumption, and instead prioritizes revenue generation. Officials proposed adding a ninth tier to the existing structure to encourage illegal producers to enter the formal market, with potential implementation as early as May 2026.
Critics argue the move could complicate the system and enable “downtrading,” where consumers shift to cheaper products, while also creating opportunities for manipulation and weak enforcement. CISDI recommended simplifying the current structure rather than expanding it, and ICW warned that additional tiers could open new avenues for corruption through product misclassification. Government officials maintain the policy could help increase revenue and curb illicit trade, but civil society groups say it does not address underlying enforcement challenges.
Cambodia’s Ministry of Education, Youth and Sport issued a directive banning the use, sale, and advertising of all tobacco products, including e-cigarettes, across a wide range of public spaces, particularly those linked to education and sports. The ban covers schools, training centers, dormitories, workplaces, gyms, and sports venues, and also prohibits the distribution and promotion of such products in and around these locations. Authorities have been instructed to implement health awareness programs and work with parents to identify and report violations for enforcement action.
Education Minister Hang Chuon Naron said the measures align with broader government restrictions targeting the import, sale, possession, and production of electronic smoking devices and shisha products. Health experts noted that tobacco use remains prevalent despite existing public smoking bans and called for stronger enforcement.
Drew Estate announced plans to expand into the Dominican Republic with a new manufacturing and agricultural project, Drew Dominicana, expected to open in early 2027, according to the Premium Cigar Association. The development includes a 73,000-square-foot cigar factory in Santiago and a dedicated tobacco farm in Villa González, marking the first time the company will produce cigars outside of Nicaragua, where its operations have historically been based. The company said most production will remain at its Estelí facility, while certain brands, including Deadwood Tobacco Co. Dominicana and Undercrown El Tigre Dominicano, are expected to transition to the new site once operational.
The project will focus on tobacco cultivation, cigar production, and consumer-facing experiences. Drew Estate said the farm will grow tobacco exclusively for the company and will be led by Dominican cultivator Manuel Peralta. Company executives described the expansion as a long-term strategic investment, with additional details on production and future releases to be announced as development progresses.
Why the World Cannot Afford America’s Regulatory Model
By Dr. J. Preston Campbell, Cancer Researcher, Harm Reduction Scientist
Heavy lifetime smoking kills approximately half of long-term users. That is not a projection or a model output — it is one of the most replicated findings in twentieth-century epidemiology, confirmed across decades and continents (WHO, 2023). In the United States alone, tobacco-attributable disease generates an estimated $310 billion in annual healthcare costs, roughly $6,500 per smoker per year (Xu et al., 2015; ASH, 2021). Globally, the burden exceeds $1.4 trillion annually (WHO, 2023). We know what is causing the damage. We have products that demonstrably reduce it. The question worth asking — the one this analysis is organized around — is why those products cost 167 times more per life saved to bring to market in the United States than in the European Union.
The Health Economics Punchline
Nicotine pouches are, by most objective measures, one of the less scientifically interesting harm- reduction products ever developed. No combustion. No inhalation. No tobacco leaf. Pharmaceutical-grade nicotine salt in a cellulose pouch placed between lip and gum for thirty minutes. Peer-reviewed toxicant studies document 95–99% lower exposure to carcinogens compared to cigarettes (Mallock et al., 2019; Snusforumet, 2021). The first Cochrane systematic review, published October 2025, found no serious adverse events across all trials and confirmed consistently reduced toxicant biomarkers in every switching cohort studied (Hartmann-Boyce et al., 2025). The product’s risk profile is not controversial. What is controversial, apparently, is the cost of allowing it to be sold.
The standard health-economic metric for evaluating interventions is cost per quality-adjusted life year (QALY) gained — a single number that combines how long and how well someone lives. The U.S. cost-effectiveness threshold is $50,000–$100,000 per QALY. Published ICER estimates for comparable nicotine delivery products run $7,500/QALY for NRT sampling programs and $11,454/QALY for e-cigarettes used as cessation aids (Maciosek et al., 2022; Masiero et al., 2025). Based on the observed 5.2% switch rate in national survey data and the documented 95% risk reduction from switching, nicotine pouches are estimated to fall in the $3,000–$15,000/QALY range — well inside the cost-effectiveness frontier by any standard (Delnevo et al., 2024; Goniewicz et al., 2025).
At that switch rate, applying regulatory entry costs to the lives saved annually from harm reduction produces Figure 1.
The U.S. costs $201 per statistical life saved per year. The EU costs $1.20. Sub-Saharan Africa costs $0.47. These numbers do not argue that FDA should wave products through without review. They argue something more specific: that a regulatory framework costing 167 times more per life saved than its closest comparator is not optimizing for public health outcomes. It is optimizing for something else.
Why: The Entry Cost Structure
The reason is straightforward once the numbers are placed side by side.
In the United States, bringing a single nicotine pouch product line to market requires a Premarket Tobacco Application. FDA’s own published cost estimate of $117,000–$466,563 per application (FDA, 2021a) has not aged well. Industry experience places the all-in cost at $4.2–$7.2 million per product family, once pharmacokinetic trials ($1M+), 12-month stability studies ($250K+), consumer perception research, addiction liability assessments, and regulatory consulting are properly accounted for (Broughton Group, 2025; JJCC Group, 2026). ZYN’s January 2025 marketing authorization — the first for this product class — took years and the resources of a Fortune 500 company (FDA, 2025a).
Elsewhere, the numbers describe a different regulatory universe. EU notification under the Tobacco Products Directive: $30,000–$80,000 per market. UAE ECAS registration: $35,000. Saudi Arabia: $27,000. Egypt — an open market of 14.5 million smokers — $15,000 (Broughton Group, 2025; SGS, 2025; author analysis). A company could simultaneously enter the EU’s 110 million-smoker market, Japan, South Korea, UAE, Saudi Arabia, Egypt, and sub-Saharan Africa for less than one U.S. PMTA submission.
Why It Is Worse Than It Looks:The Time Factor
Entry cost alone understates the problem. The PMTA requires a minimum of 15 months of mandatory studies before submission, followed by an FDA review period averaging over three years to date (FDA, 2025b; Tobacco Law Blog, 2025). From the date a company decides to enter the U.S. market, the minimum realistic timeline to first legal sale is 51 months — over four years. The EU takes 9 months. The UAE and Saudi Arabia: 6 months. Egypt and sub-Saharan Africa: 3 months (author analysis).
When those timelines are applied to financial models — discounting future revenue at the 20% rate typical for early-stage consumer products and adjusting for denial risk (estimated at 35% for new U.S. entrants; FDLI, 2023) — the picture becomes harder to rationalize from any direction.
The EU, despite having roughly half the U.S. annual revenue potential, generates a 5-year risk-adjusted NPV of $109.5 million compared to the U.S. at $47.3 million — because it begins generating cash 42 months earlier at one-tenth the cost. The U.S. payback period from today to regulatory cost recovery is 5.2 years, compared to 1.8 years for the EU and 1.2 years for Egypt. The U.S. is the only market in this analysis that exceeds the standard 2-year payback threshold that most venture and growth-equity investors apply to consumer product categories (Alacrita, 2024). During the 48-month excess waiting period, a company forfeits approximately $270 million in gross margin that would otherwise accrue in markets where the same product is already legally sold.
The 5-year ROI multiple on regulatory spend, risk-adjusted: 55× for the U.S., compared to 3,135× for the EU and 1,465× for sub-Saharan Africa. The PMTA does not just cost more — it structurally consumes the financial return from market participation, leaving only companies with institutional balance sheets able to absorb it.
The Cessation Paradox FDA Built
Here is where it gets genuinely strange.
FDA’s own authorization of ZYN stated explicitly that the products “have the potential to provide a benefit to adults who smoke cigarettes and would like to switch to a lower-risk alternative” (FDA, 2025a). The PMTA submissions included cessation and switching behavior data. FDA reviewed them. FDA relied on them to issue authorization.
And then FDA’s post-authorization communications carefully noted that the products are “not FDA approved” and that “there is no safe tobacco product” — language that systematically prevents companies from communicating the public health rationale that justified the authorization (FDA, 2025a).
Under the Tobacco Control Act, tobacco products cannot make cessation claims. If a company wants to say anything about reduced risk, it must file a separate Modified Risk Tobacco Product application — another process, more years, more millions, with public comment periods, advisory committee referrals, and post-market surveillance requirements (FDA, 2025c). As of 2024, FDA had received 48 MRTP applications since 2010 and authorized exactly 16 products (LDI Penn, 2025).
The logic chain deserves a slow read: FDA required switching studies as a PMTA condition. It reviewed them. It relied on them to grant authorization. It then prohibited companies from telling consumers those studies existed. The MRTP pathway functions in practice as a second admission ticket for a claim FDA already accepted as scientifically valid during the PMTA review. This is not a minor regulatory inconvenience. It is the architecture of a system in which harm reduction is simultaneously required as scientific evidence and forbidden as commercial communication.
What Rational Regulation Would Look Like
FDA’s September 2025 nicotine pouch pilot program demonstrated that rigorous and efficient review are not mutually exclusive (Tobacco Law Blog, 2025). The on! PLUS authorization in December 2025 confirmed it. Real-time applicant communication, literature-based study requirements, and focused critical element review cut timelines dramatically without any evidence of compromised standards (FDA, 2026).
That pilot should be the floor, not the ceiling. A product class with documented 95–99% lower toxicant exposure, no combustion, no inhalation, no tobacco leaf, and no serious adverse events in any trial conducted to date (Hartmann-Boyce et al., 2025) does not require the evidentiary apparatus of a novel pharmaceutical. The rest of the world has largely reached this conclusion.
In the meantime, 47.7 million Americans who smoke continue using a product that kills approximately half of them — while regulators elsewhere issue notifications, complete registrations, and authorize sales. At $201 per life saved, the U.S. PMTA process is not the problem. The problem is that it is 167 times more expensive than the alternative, without any measurable difference in the public health outcomes it is designed to protect.
_____________________________________
J. Preston Campbell, PhD, is a cancer researcher, harm reduction scientist, and co-founder of multiple companies, currently focusing on ENSO, his consulting and formulation company. His work focuses on translating reduced-risk nicotine products from laboratory science to regulatory approval and commercial deployment.
